GlobalData reports Ozempic price cut to slow consumer shift toward alternative treatments
The company aims to make FDA approved semaglutide therapies safer and more financially accessible, compared to compounded weight-loss alternatives.
GLP-1
UVA Health experts warn GLP-1 drugs may not provide key long-term weight-loss benefit
Doctors may need to consider recommending exercise programs or develop other approaches, such as nutrition supplements or complementary medications, to help GLP-1 patients get the full cardiorespiratory benefits of substantial weight loss over the long-run, the researchers say.
WeightWatchers and Novo Nordisk expand partnership
WeightWatchers clinic members can access FDAapproved Wegovy for $299 in July.
Scripta Insights launches GLP-1 Navigator
New member app feature delivers trusted, clinician-backed guidance as millions face GLP-1 access setbacks after CVS Caremark drops Zepbound and WeightWatchers files for bankruptcy.
New study challenges GLP-1 norms with strong results on a fraction of the usual dose
In one of the largest and longest real-world obesity studies to date, Embla tracked nearly 2,700 adults over 64 weeks and achieved 16.7% average weight loss using 66% less semaglutide than typical U.S. doses.
Charles Barkley teams with Ro as GLP-1 Celebrity Ambassador
The NBA legend is spotlighting convenient access to weight loss treatment with Ro.
New report from GoodRx tracks changes in GLP-1 insurance coverage
In 2025, the number of people without commercial insurance coverage for these medications surged significantly. Zepbound saw a 14% increase since 2024, leaving 4.9 million people without coverage, and Ozempic saw a 22% increase, affecting another 1.1 million people.